Fixed dose daptomycin: An opportunity for pharmacokinetic/pharmacodynamic optimization in Staphylococcus aureus infections
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · 2024
DOI: 10.1002/phar.4602 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2024. Verfasst von Katie B Olney und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, University of Kentucky HealthCare, Lexington, Kentucky, USA. Hauptthemen laut MEDLINE: Daptomycin, Anti-Bacterial Agents, Staphylococcal Infections. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 24 Literaturangaben. Gefördert von: Society of Infectious Diseases Pharmacists (SIDP).
Abstract (Originalsprache)
Background
Daptomycin is a high‐use intravenous antimicrobial agent affording the convenience of once‐daily dosing. Prior studies suggest an opportunity to use a more operationally convenient fixed rather than weight‐based dosing but this approach has not been studied prospectively.
Methods
This study quantified the probability of toxicity and efficacy end points by prospectively testing a fixed dose regimen of daptomycin (750 mg) in obese and non‐obese adults. At least, three daptomycin concentrations were measured at steady‐state for each patient. A population pharmacokinetic model was constructed to evaluate concentration‐time profiles and investigate covariates of daptomycin clearance. Simulations were performed to evaluate the probability of achieving efficacy (24‐h area under the curve (AUC 0‐24 ) ≥ 666 mg∙h/L) and toxicity (minimum concentration ( C min ) ≥24.3 mg/L) targets for fixed (500–1000 mg) and weight‐based (6–12 mg/kg) daptomycin doses.
Results
Thirty‐one patients (16 females, 15 males) with median (interquartile range (IQR)) age of 50 (30, 62) years and weight of 74 (54, 156) kg were included in the final analysis. Fixed dose daptomycin (750 mg) resulted in similar exposure across weights with a median (IQR) AUC 0‐24 of 819 (499, 1501) mg∙h/L and 749 (606, 1265) mg∙h/L in patients weighing ≤74 kg and >74 kg, respectively. Overall, male sex and increased kidney function necessitate higher fixed and weight‐based doses to achieve efficacy. Creatine phosphokinase elevation was observed in two patients (6.5%) and predicted to be lower with fixed versus weight‐based regimens.
Conclusions
Fixed daptomycin dosing adjusted for sex and kidney function is expected to improve the efficacy‐to‐toxicity ratio, transitions of care, and costs compared to weight‐based doses. However, no empiric dosing approach is predicted to achieve ≥90% efficacy while minimizing the risk of toxicity, so therapeutic drug monitoring should be considered on a patient‐specific basis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, University of Kentucky HealthCare, Lexington, Kentucky, USA.
- Department of Pharmacy Practice and Science, The University of Kentucky College of Pharmacy, Lexington, Kentucky, USA.
- Department of Clinical Pharmacy, University of Michigan College of Pharmacy, Ann Arbor, Michigan, USA.
- Division of Infectious Diseases, University of Kentucky HealthCare, Lexington, Kentucky, USA.
- University of KwaZulu-Natal School of Clinical Medicine, Durban, South Africa.
ORCID-Profile: Katie B Olney, Manjunath P Pai, Jenni K Thomas, William J Olney, Rebecca A Bruning, David S Burgess
Förderung
- Society of Infectious Diseases Pharmacists (SIDP)
Zitieren
APA
Olney, K. B., Pai, M. P., Thomas, J. K., Burgess, D. R., Olney, W. J., Bruning, R. A., Griffith, K. A., Casaus, D. V., Crance, E., Porterfield, J. Z., & Burgess, D. S. (2024). Fixed dose daptomycin: An opportunity for pharmacokinetic/pharmacodynamic optimization in Staphylococcus aureus infections. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. https://doi.org/10.1002/phar.4602
Vancouver
Olney KB, Pai MP, Thomas JK, Burgess DR, Olney WJ, Bruning RA, et al. Fixed dose daptomycin: An opportunity for pharmacokinetic/pharmacodynamic optimization in Staphylococcus aureus infections. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 2024. doi:10.1002/phar.4602
BibTeX
@article{Olney2024,
author = {Olney, Katie B and Pai, Manjunath P and Thomas, Jenni K and Burgess, Donna R and Olney, William J and Bruning, Rebecca A and Griffith, Kamron A and Casaus, Danielle V and Crance, Elizabeth and Porterfield, James Z and Burgess, David S},
title = {Fixed dose daptomycin: An opportunity for pharmacokinetic/pharmacodynamic optimization in Staphylococcus aureus infections},
journal = {Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy},
year = {2024},
doi = {10.1002/phar.4602}
}
EUVIMED